Stockscreener 앱 받기
126.61
0.48%
-0.8101
전일 마감가:
$127.42
열려 있는:
$127.33
하루 거래량:
2.71M
Relative Volume:
0.46
시가총액:
$220.99B
수익:
$41.95B
순이익/손실:
$13.40B
주가수익비율:
16.55
EPS:
7.65
순현금흐름:
$6.35B
1주 성능:
-2.37%
1개월 성능:
-4.78%
6개월 성능:
+11.53%
1년 성능:
+13.73%
1일 변동 폭
$126.49
$127.76
1주일 범위
$124.50
$128.62
52주 변동 폭
$99.71
$140.84
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
ABT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
126.64 | 220.99B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
101.34 | 148.66B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
374.04 | 144.26B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
91.12 | 115.99B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.72 | 41.68B | 5.72B | 4.17B | 259.90M | 6.97 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
What Does the Market Think About Abbott Laboratories? - Benzinga
Abbott’s world-first portable whole blood rapid test for concussions launches in the UK (2) - PharmiWeb.com
U.S. Clinical Nutrition Market Is Booming Worldwide 2025-2032 | - openPR
Medtronic, Abbott Block Boston Scientific Heart Valve IP - Law360
Abbott launches portable concussion blood test in UK - Medical Device Network
Abbott Laboratories: An Insight Into Its Medtech & Diagnostic Growth Trajectory & Why It May Not Be Enough To Warrant A ‘Buy’ Rating! - Smartkarma
Brazil Enteral Nutrition Market Is Booming Worldwide 2025-2032 - openPR
Medical Nutrition Market Key Players Analysis- Abbott - openPR
RFK Jr.’s Next Targets Are Companies Making Baby Formula - Yahoo Finance
US health agencies announce plan to strengthen infant formula supply and quality -March 18, 2025 at 02:23 pm EDT - Marketscreener.com
Abbott Laboratories (ABT): Among the Best Diabetes Stocks to Buy According to Billionaires - Insider Monkey
Decoding Abbott Laboratories's Options Activity: What's the Big Picture? - Benzinga
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views? - Nasdaq
Personalized Vitamins Market Top Players- BASF SE, Abbott Laboratories. Amway Corporation, Bayer AG, Caligenix. - openPR
Abbott's Narrow Economic Moat Rests on a Solid Product Portfolio - Morningstar
Abbott Laboratories Gains 12.7% in a Year: What's Driving the Stock? - MSN
Blood Typing Analysis Report 2024: Market Set to Surge to $6.50 Billion by 2034, PCR and Microarray Techniques Pave the Way - GlobeNewswire Inc.
Abbott Stock Could Be On The Verge Of A Breakout — Here’s What Smart Money Sees (NYSE:ABT) - Seeking Alpha
Reckitt’s Mead Johnson, Abbott to face new trial in US infant-formula case - just-food.com
Abbott Laboratories Insiders Sell US$3.3m Of Stock, Possibly Signalling Caution - Yahoo Finance
Abbott Laboratories' (NYSE:ABT) earnings growth rate lags the 15% CAGR delivered to shareholders - Simply Wall St
Abbott Laboratories Basking In A Sharp Turn In Sentiment (NYSE:ABT) - Seeking Alpha
Why Abbott Laboratories (ABT) Went Down On Thursday? - MSN
Why Abbott Laboratories (ABT) Went Down On Friday? - Insider Monkey
Abbott Labs, Reckitt Benckiser Shares Fall After New Ruling on Infant Formula Case - The Wall Street Journal
Baby Formula Makers Abbott and Reckitt See Stocks Slide as Judge Allows Retrial - Investopedia
In a setback for Abbott Laboratories, judge allows new trial in case over formula for premature infants - Chicago Tribune
Judge Vacates Baby Formula Trial Win For Abbott, Mead - Law360
‘A Manifest Injustice': Judge Who Sanctioned Abbott’s Counsel Grants New Infant Formula Trial - Law.com
Sector Update: Health Care -March 14, 2025 at 03:29 pm EDT - Marketscreener.com
BofA keeps $150 target on Abbott Labs stock amid retrial news - Investing.com
Abbott, Reckitt Fall as Judge Grants New Trial on Infant Formula - Bloomberg
Abbott, Reckitt face new trial over premature infant formula - Reuters
That baby formula trial Abbott and Reckitt won isn't over just yet - Crain's Chicago Business
Judge orders retrial in Abbott, Reckitt infant formula case - Seeking Alpha
Citi maintains Abbott stock Buy rating, $160 target amid legal updates By Investing.com - Investing.com South Africa
Is Abbott Laboratories (ABT) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
Citi maintains Abbott stock Buy rating, $160 target amid legal updates - Investing.com
Abbott, Reckitt face new trial over premature infant formula -March 14, 2025 at 11:09 am EDT - Marketscreener.com
Positive Long-Term Outlook for Abbott Laboratories Despite Short-Term NEC Litigation Risks - TipRanks
Abbott sends film crew to highlight partnership with Auburn Community Hospital - The Citizen
Abbott stock falls following retrial order in infant formula case - Investing.com
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.
Abbott (ABT) Stock Moves -0.3%: What You Should Know - Nasdaq
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - MSN
Abbott (ABT) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Glucose Biosensor Market Booming with Technological Advancements | Industry Insights Abbott Laboratories, - EIN News
Here's Why We Think Abbott Laboratories (NYSE:ABT) Might Deserve Your Attention Today - Yahoo Finance
OTC Consumer Health Market Positioned for Accelerated Growth with Johnson&Johnson, Abbott Laboratories, - EIN News
EPD Expansion Supports Abbot Stock, Macro Issues Prevail - TradingView
Neurological Biomarkers: Global Market Review 2020-2024 and - GlobeNewswire
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.47%
1.21%
자본화:
|
볼륨(24시간):